Jazz Pharmaceuticals plc Boeing Bond
J7Z Stock | EUR 118.85 1.70 1.45% |
Jazz Pharmaceuticals plc has over 6.02 Billion in debt which may indicate that it relies heavily on debt financing. . Jazz Pharmaceuticals' financial risk is the risk to Jazz Pharmaceuticals stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Jazz Pharmaceuticals' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Jazz Pharmaceuticals' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Jazz Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Jazz Pharmaceuticals' stakeholders.
For most companies, including Jazz Pharmaceuticals, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Jazz Pharmaceuticals plc, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Jazz Pharmaceuticals' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Jazz |
Given the importance of Jazz Pharmaceuticals' capital structure, the first step in the capital decision process is for the management of Jazz Pharmaceuticals to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Jazz Pharmaceuticals plc to issue bonds at a reasonable cost.
Popular Name | Jazz Pharmaceuticals Boeing Co 2196 |
Equity ISIN Code | IE00B4Q5ZN47 |
Bond Issue ISIN Code | US097023DG73 |
S&P Rating | Others |
Maturity Date | 4th of February 2026 |
Issuance Date | 4th of February 2021 |
Coupon | 2.196 % |
Jazz Pharmaceuticals plc Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
MPLX LP 4875 | US55336VAG59 | Details | |
MPLX LP 4125 | US55336VAK61 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
Morgan Stanley 3971 | US61744YAL20 | Details | |
MGM Resorts International | US552953CD18 | Details | |
Valero Energy Partners | US91914JAA07 | Details |
Understaning Jazz Pharmaceuticals Use of Financial Leverage
Jazz Pharmaceuticals' financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Jazz Pharmaceuticals' total debt position, including all outstanding debt obligations, and compares it with Jazz Pharmaceuticals' equity. Financial leverage can amplify the potential profits to Jazz Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Jazz Pharmaceuticals is unable to cover its debt costs.
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc. Codiak BioSciences, Inc. Pfenex, Inc. and XL-protein GmbH. JAZZ PHARMACEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1460 people. Please read more on our technical analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Jazz Stock
When determining whether Jazz Pharmaceuticals plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Jazz Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Jazz Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Jazz Pharmaceuticals Plc Stock:Check out the analysis of Jazz Pharmaceuticals Fundamentals Over Time. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.